BioMarin (BMRN) PT Raised to $120 at BofA Securities Given Higher Confidence in Roctavian Approval
Tweet Send to a Friend
BofA Securities analyst Geoff Meacham raised the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $120.00 (from $115.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
